Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ImmunoCellular Therapeutics, Ltd. | rrd408601.htm |
| EX-99 - PRESS RELEASE, DATED MAY 8, 2014 - ImmunoCellular Therapeutics, Ltd. | rrd408601_40706.htm |
| Exhibit 99.2 | ||||||||
| Condensed Balance Sheets | ||||||||
| 3/31/2014 | 12/31/2013 | |||||||
| (unaudited) | ||||||||
|
|
|
|
||||||
| Cash | $ | 25,029,393 | $ | 27,646,351 | ||||
| Other current assets | 732,372 | 763,299 | ||||||
| Non current assets | 521,597 | 531,027 | ||||||
|
|
|
|
|
|||||
| $ | 26,283,362 | $ | 28,940,677 | |||||
|
|
|
|
|
|||||
| Current liabilities | $ | 1,306,766 | $ | 1,402,273 | ||||
| Warrant liabilities | 1,480,877 | 1,064,810 | ||||||
| Shareholders' equity | 23,495,719 | 26,473,594 | ||||||
|
|
|
|
|
|||||
| $ | 26,283,362 | $ | 28,940,677 | |||||
|
|
|
|
|
|||||
| Condensed Statements of Operations (unaudited) | ||||||||
| Three months | Three months | |||||||
| ended | ended | |||||||
| 3/31/2014 | 3/31/2013 | |||||||
|
|
|
|
|
|||||
| Revenue | $ | - | $ | - | ||||
| Research and development | 1,699,760 | 1,415,261 | ||||||
| Stock based compensation | 184,102 | 164,128 | ||||||
| General and administrative | 865,402 | 769,267 | ||||||
|
|
|
|
|
|||||
| Loss before other expenses | (2,749,264) | (2,348,656) | ||||||
| Interest income | 3,354 | 6,548 | ||||||
| Change in fair value of warrant liabilities | (416,067) | (2,631,683) | ||||||
|
|
|
|
|
|||||
| Net loss | $ | (3,161,977) | $ | (4,973,791) | ||||
|
|
|
|
|
|||||
| Net loss per share, basic and diluted: | $ | (0.05) | $ | (0.10) | ||||
|
|
|
|
|
|||||